Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

NCT01405911 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

242

Enrollment

INDUSTRY

Sponsor class

Conditions

Glucose Intolerance

Interventions

DRUG: Placebo for Sitagliptin 25 mg
DRUG: Placebo for Sitagliptin 50 mg
DRUG: Sitagliptin 25 mg
DRUG: Sitagliptin 50 mg

Sponsor

Merck Sharp & Dohme LLC